At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TELO Telomir Pharmaceuticals
Closed Good Friday 04-17 16:00:00 EDT
2.48
-0.01
-0.40%
盘后2.36
-0.12-4.84%
19:27 EDT
| High2.65 | Low2.38 | Vol56.08K |
| Open2.47 | D1 Closing2.49 | Amplitude10.84% |
| Mkt Cap73.81M | Tradable Cap43.69M | Total Shares29.76M |
| T/O137.74K | T/O Rate0.32% | Tradable Shares17.62M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Telomir Pharmaceuticals Says Telomir-1 Reduces Tumor Size in Prostate Cancer Animal Model
MT Newswires Live · 03-19
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells
ACCESS Newswire · 03-19
Telomir Pharmaceuticals Inc - Telomir-1 Reduces Tumor Size by Approximately 50% in Preclinical Study
THOMSON REUTERS · 03-19
Telomir Pharmaceuticals - Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model
THOMSON REUTERS · 03-19
TELO Study Shows Cancer-Related Breakthrough
Zacks Small Cap Research · 03-19
Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines
ACCESS Newswire · 02-26
Telomir Pharmaceuticals Inc - Telomir-1 Reduces Intracellular Calcium Overload & Mitigates Oxidative Stress
THOMSON REUTERS · 02-25
Telomir Pharmaceuticals Says Telomir-1 Compound Stabilizes Silver for Advanced Medical Applications
MT Newswires Live · 02-21
Telomir says captured, stabilized silver in biologically compatible form
TIPRANKS · 02-21
Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market
ACCESS Newswire · 02-21
TELO Announces Breakthrough
Zacks Small Cap Research · 02-21
Telomir Pharmaceuticals, Inc. (TELO) Receives a New Rating from Rodman & Renshaw
TIPRANKS · 02-21
Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)
ACCESS Newswire · 02-18
Telomir Pharmaceuticals: Telomir-1 Treatment Resulted in a Significant Reduction of Ros Elevation
THOMSON REUTERS · 02-18
TELO Again Announces Breakthrough Results
Zacks Small Cap Research · 02-18
Telomir Pharmaceuticals files $150M mixed securities shelf
TIPRANKS · 02-14
Telomir Pharmaceuticals Inc Files for Mixed Shelf of up to $150 Mln - SEC Filing
THOMSON REUTERS · 02-14
TELO Improves Balance Sheet
Zacks Small Cap Research · 02-05
Telomir Pharmaceuticals announces results from preclinical studies of Telomir-1
TIPRANKS · 01-28
Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses
ACCESS Newswire · 01-28
Introduction
Company Name.
Telomir Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App